Prepared by Dr. Raj Patel, CFA, Senior Equity Strategist | Reviewed by Priya Sharma, Lead Editor | Report ID: IGEMINI-9F1350E3-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns carl moyer net worth a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 30.35x, 37.2% revenue expansion, and an RSI of 37 suggesting a neutral-bullish phase. We define critical support at $202.5 and resistance at $247.5.
Rating: Accumulate | Target Price: $303.75 | Next Earnings: Jul 09
Download Full PDF Report
MACD printed a Bearish Divergence as the 50-day SMA turned positive 19 days ago.
RSI at 37 indicates a neutral-bullish state. Historical backtests suggest a +5.2% move within 10 sessions.
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $258.75 would be bullish.
With a market cap of $1.38B, carl moyer net worth operates in Healthcare. P/E of 30.35x is backed by 37.2% growth.
Free cash flow conversion remains robust at 65%, supporting the 0.67% dividend and buybacks.
Relative to Healthcare peers, carl moyer net worth sits at the 69th percentile in valuation, offering a potential value opportunity.
Options skew is toward call at the 225 strike, positioning for a directional move.
Beta of 1.32 suggests carl moyer net worth is {beta_desc} volatile than the market, influencing hedging strategies.
Short float at 4.5% is below the sector average, reducing squeeze risk. Institutional ownership is 85%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $225 | $213.75 |
| Market Cap | $1.38B | $1.1B |
| P/E Ratio | 30.35x | 25.8x |
| EPS (TTM) | $7.41 | $6.67 |
| Dividend Yield | 0.67% | 0.5% |
| Revenue Growth | 37.2% | 22.3% |
| Target Price | $303.75 | - |
| Beta | 1.32 | 1.00 |